Acetylsalicylic acid in the practice of a therapist
Kashtalap V.V.^1,2, Barbarash O.L.<sup>1.2

1</sup> Kuzbass Cardiology Center, Kemerovo
² Kemerovo State Medical Univesity

The article presents the current state of the use of acetylsalicylic acid (ASA) in the practice of a physician based on current clinical recommendations and the results of randomized clinical trials. The advantage of using enteric forms of the drug is shown. The mechanism of antiplatelet action of ASA is described. The possibilities of using ASA for primary and secondary prevention of atherothrombotic complications of ischemic heart disease are discussed in detail. The evidence base for the long-term use of aspirin for the prevention of such repeated cardiovascular events as myocardial infarction, unstable angina, ischemic stroke, and associated mortality is now undoubted. Long-term use of ASA for primary prevention of cardiovascular events by persons without clinical manifestations of atherosclerosis does not provide a reduction in cardiovascular mortality and at the same time increases the incidence of large gastrointestinal and extracranial bleeding. The issues of safety of ASA and the possibility of reducing the risk of gastropathy are considered. Additional effects of acetylsalicylic acid on the prevention of certain forms of oncopathology are shown. So the daily use of aspirin in a dosage of 75–100 mg is associated with a decrease in the risk of colorectal cancer and other types of oncology.

Key words: atherothrombosis, ischemic heart disease, cardiovascular diseases, cardiovascular mortality, acute coronary syndrome, acetylsalicylic acid, aspirin, Sanovasc.
For citation: Kashtalap V.V., Barbarash O.L. Acetylsalicylic acid in the practice of a therapist // RMJ. 2018. № 6(I). P. 25–28.